Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Maertens

Showing results (251-260 of 361) with videos related to

Pageof 37
Sort By:
Cancer|October 29, 2020
Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationGiorgia Battipaglia, Myriam Labopin, Rose-Marie Hamladji, et al.
Haematologica|March 26, 2026
Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy <i>versus</i> liposomal cytarabine and daunorubicinDimitrios Kotsos, Patrycja Gradowska, Sjoerd J F Hermans, et al.
Blood|January 28, 2010
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 studyBob Löwenberg, Joachim Beck, Carlos Graux, et al.
The Journal of Infectious Diseases|January 19, 2011
The Y238X stop codon polymorphism in the human β-glucan receptor dectin-1 and susceptibility to invasive aspergillosisLouis Y A Chai, Mark G J de Boer, Walter J F M van der Velden, et al.
Cancer|April 6, 2024
Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation studyJustin Loke, Myriam Labopin, Charles Craddock, et al.
Bone Marrow Transplantation|July 3, 2025
Impact of pre-transplant induction cycles on post-transplant outcomes in patients with ALL: a study from the ALWP EBMTJuan Montoro, Allain-Thibeault Ferhat, Nathalie Dhedin, et al.
The Journal of Infectious Diseases|March 4, 2026
Treatment Monitoring and Outcome Prediction in Invasive Aspergillosis using Immunologic MarkersAna Pereira, Jennifer Scott, Andrei Sarlea, et al.
British Journal of Haematology|March 2, 2019
Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemiaNicolaus Kröger, Diderik-Jan Eikema, Linda Köster, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2017
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q DeletionLaurent Garderet, Dimitris Ziagkos, Anja van Biezen, et al.
Bone Marrow Transplantation|August 2, 2024
Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMTRama Al Hamed, Myriam Labopin, Depei Wu, et al.
Pageof 37

Showing results (251-260 of 361) with videos related to

Sort By:
Pageof 37
Cancer|October 29, 2020
Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationGiorgia Battipaglia, Myriam Labopin, Rose-Marie Hamladji, et al.
Haematologica|March 26, 2026
Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy <i>versus</i> liposomal cytarabine and daunorubicinDimitrios Kotsos, Patrycja Gradowska, Sjoerd J F Hermans, et al.
Blood|January 28, 2010
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 studyBob Löwenberg, Joachim Beck, Carlos Graux, et al.
The Journal of Infectious Diseases|January 19, 2011
The Y238X stop codon polymorphism in the human β-glucan receptor dectin-1 and susceptibility to invasive aspergillosisLouis Y A Chai, Mark G J de Boer, Walter J F M van der Velden, et al.
Cancer|April 6, 2024
Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation studyJustin Loke, Myriam Labopin, Charles Craddock, et al.
Bone Marrow Transplantation|July 3, 2025
Impact of pre-transplant induction cycles on post-transplant outcomes in patients with ALL: a study from the ALWP EBMTJuan Montoro, Allain-Thibeault Ferhat, Nathalie Dhedin, et al.
The Journal of Infectious Diseases|March 4, 2026
Treatment Monitoring and Outcome Prediction in Invasive Aspergillosis using Immunologic MarkersAna Pereira, Jennifer Scott, Andrei Sarlea, et al.
British Journal of Haematology|March 2, 2019
Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemiaNicolaus Kröger, Diderik-Jan Eikema, Linda Köster, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2017
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q DeletionLaurent Garderet, Dimitris Ziagkos, Anja van Biezen, et al.
Bone Marrow Transplantation|August 2, 2024
Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMTRama Al Hamed, Myriam Labopin, Depei Wu, et al.
Pageof 37